Pfizer Deal To Help Propel Aurobindo's Revenues To $2 Billion In Three Years
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD, India - With fifteen manufacturing sites under its belt and a comprehensive outsourcing deal with Pfizer, India's Aurobindo Pharma expects to see a huge bounce in its revenues from the present $800 million to over $2 billion in a span of three years
You may also be interested in...
With An Import Alert, India's Aurobindo Reels Under U.S. FDA Glare; Four Pfizer Products Impacted
MUMBAI - In what is being described as a body blow to the reputation of Indian drug companies, U.S. FDA imposed an import alert against one manufacturing site of Aurobindo Pharma located near the central Indian city of Hyderabad
With An Import Alert, India's Aurobindo Reels Under U.S. FDA Glare; Four Pfizer Products Impacted
MUMBAI - In what is being described as a body blow to the reputation of Indian drug companies, U.S. FDA imposed an import alert against one manufacturing site of Aurobindo Pharma located near the central Indian city of Hyderabad
Buoyed By Big Offers And Repository of Data, Aurobindo Branches Out Into CRAMS Business With Aurosource
HYDERABAD, India - Athough a relatively late entrant into the contract research and manufacturing space in India, Aurobindo Pharma with its new logo "Nothing compromised" thinks there is still enough room to forge credible relationships with Western companies for newly floated CRAMS unit Aurosource